This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Epidemiologist Dr. Eric Feigl-Ding joined Closing Bell to explain why ending the travel mask mandates could put the U.S. in a bad position in the coming months as new COVID-19 variants threaten to cause another spike in cases.
Laurence Tribe, a professor of constitutional law at Harvard University, joined Cheddar News to talk about the legal underpinnings of the ruling to lift the federal travel mask mandate. "Judge Mizelle decided that she would issue a nationwide injunction, which she and other conservatives have criticized in the past," he said. "That didn't stop her from doing it this time. She did it by just wiping away the CDC's rule, and she did it, have to say, in an opinion that was, well, I'll be honest, really stupid."
After a nationwide mask mandate for travel was struck down by a federal judge, Dr. Sampson Davis, an ER physician and bestselling author, joined Cheddar News to talk about the ramifications. "We are at a place where we are going to have to wait and see, unfortunately," he said. "The good news is that we're coming off a celebration of spring break, Easter, Passover, and we'll see what happens. But right now I'm not seeing a spike and people come into the hospital are truly sick. However, I'm still seeing people test positive for COVID."
Apple has revealed that the tech giant is working more on going green, reporting the use of more recycled materials than ever before. It's setting sustainability goals, aiming to cut emissions by 75 percent in the next 10 years and eventually ending the use of plastic in packaging.
Will Marshall, CEO, Planet, joins Cheddar Reveals to discuss Planet's influence and innovation from agriculture to sustainability using geospatial insights from their constellation of over 200 satellites.
Thomas Zurbuchen, Associate Administrator, NASA Science, joins Cheddar Reveals to break down the future of space exploration and how NASA is innovating this year and into the next decade.
Catching you up on what you need to know on April 19, 2022, with a federal judge voiding mask mandates on public transportation, updates from the Russia and Ukraine war, Mac Miller’s drug dealer sentenced for involvement in the rapper's death, and more.
A federal judge’s decision to strike down a national mask mandate was met with cheers on some airplanes but also concern about whether it’s really time to end the order sparked by the COVID-19 pandemic.
A new Axios-Ipsos poll found that just one in ten people would currently characterize the coronavirus as a serious crisis. The vast majority do believe it's a problem, but a manageable one. It's clear that the public is itching to ditch their masks and various other restrictions. Chris Jackson, senior vice president of Ipsos public affairs, joins Cheddar News.
Between Bells executive producer Conor White recaps some of the biggest stories of the week, and teaches Azia Celestino and Hena Doba a thing or two at the same time. It's This Week In Trivia!
